Precursors and Chemicals Frequently Used in the Illicit Manufacture Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017
INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org). -
COMBINED LIST of Particularly Hazardous Substances
COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane -
Synthetic Drugs: Overview and Issues for Congress
Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700 www.crs.gov R42066 Synthetic Drugs: Overview and Issues for Congress Summary Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, Congress has demonstrated a renewed concern with the issue. From 2009 to 2011, synthetic drug abuse was reported to have dramatically increased. During this time period, calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids (such as “K2” and “Spice”) and stimulants (such as “bath salts”) increased at what some considered to be an alarming rate. The number of hospital emergency department visits involving synthetic cannabinoids more than doubled from 2010 to 2011. In 2012 and 2013, however, the number of calls to poison control centers for incidents relating to harmful effects of synthetic cannabinoids and synthetic stimulants decreased. Calls regarding bath salts have declined each year since 2011, while calls regarding synthetic cannabinoids have increased since the drops in 2012 and 2013. -
2020 International Narcotics Control Strategy Report
United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2020 INCSR 2020 Volume 1 Table of Contents Table of Contents Common Abbreviations ..................................................................................................................................... iii International Agreements.................................................................................................................................... v INTRODUCTION ..................................................................................................................................... 1 Legislative Basis for the INCSR ......................................................................................................................... 2 Presidential Determination ................................................................................................................................. 7 Policy and Program Developments .................................................................................................... 12 Overview ......................................................................................................................................................... 13 Methodology for U.S. Government Estimates of Illegal Drug Production .......................................................... 18 Parties to UN Conventions .............................................................................................................................. -
The Market for Amphetamine-Type Stimulants and Their Precursors in Oceania
The market for amphetamine-type stimulants and their precursors in Oceania Andreas Schloenhardt Research and Public Policy Series No. 81 The market for amphetamine-type stimulants and their precursors in Oceania Andreas Schloenhardt Research and Public Policy Series No. 81 © Australian Institute of Criminology 2007 ISSN 1326-6004 ISBN 978 1 921185 53 3 Apart from any fair dealing for the purpose of private study, research, criticism or review, as permitted under the Copyright Act 1968 (Cth), no part of this publication may in any form or by any means (electronic, mechanical, microcopying, photocopying, recording or otherwise) be reproduced, stored in a retrieval system or transmitted without prior written permission. Inquiries should be addressed to the publisher. Project no. 0135 Published by the Australian Institute of Criminology GPO Box 2944 Canberra ACT 2601 Tel: (02) 6260 9272 Fax: (02) 6260 9299 Email: [email protected] Website: http://www.aic.gov.au Please note: minor revisions are occasionally made to publications after release. The online versions available on the AIC website will always include any revisions. Edited and typeset by the Australian Institute of Criminology A full list of publications in the Research and Public Policy Series can be found on the Australian Institute of Criminology website at http://www.aic.gov.au Director’s introduction In 2005, the United Nations Office on Drugs and Crime (2005) valued the global market for ATS at US$44 billion, approximately 13.8 percent of the global illicit drug market (at retail level). It has been estimated that Oceania accounts for about 9–10 percent of the global ATS market; a market share that is disproportionately large in relation to the small population of the region. -
A Study of the Intermediate Steps in the Preparation of Alkylphenylbarbituric Acids James Edward Doyle University of Massachusetts Amherst
University of Massachusetts Amherst ScholarWorks@UMass Amherst Masters Theses 1911 - February 2014 1933 A study of the intermediate steps in the preparation of alkylphenylbarbituric acids James Edward Doyle University of Massachusetts Amherst Follow this and additional works at: https://scholarworks.umass.edu/theses Doyle, James Edward, "A study of the intermediate steps in the preparation of alkylphenylbarbituric acids" (1933). Masters Theses 1911 - February 2014. 1468. Retrieved from https://scholarworks.umass.edu/theses/1468 This thesis is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Masters Theses 1911 - February 2014 by an authorized administrator of ScholarWorks@UMass Amherst. For more information, please contact [email protected]. A STUDY OF THE INTERMEDIATE STEPS IN THE PREPARATION OF ALKYLPHENYLBARBITURIC ACIDS JAMES EDWARD DOYLE Thesis submitted for the degree of Master of Science MASSACHUSETTS STATE COLLEGE June 1933 TABLE OF CONTENTS Page I. INTRODUCTION 1 II. THEORY AND REVIEW OF LITERATURE 2 A. Abstracts of Patents 2 B. Previous Work on Luminal 5 C. Reactions 9 D. Previous Work on Cyanophenylacetic Acid ll*. E f Previous Work on 5»5-Isopropylphenyl- barbituric Acid 17 III. EXPERIMENTAL WORK 19 A. Preparation of Luminal 19 1. Benzyl Cyanide 21 2. Ethyl Cyanophenylacetate 22 3. Ethyl Cyanoethylphenylacetate 2l\. 5,5-Sthylphenyl-^-iminobarbituric Acid25 5. 5,5-Ethylphenylbarbituric Acid 27 B. Preparation of Ethyl oc ,-f-Dicyano-oc ,f« diphenylacetoacetate 27 1. Ethyl oc ,-Y-Dicyano-cc ,v -diphenyl- acetoacetate 29 2. Ethyl y-Cyano-oc ,Y -diphenylacetoacetate 3 2 C. Preparation of Cyanophenylacetic Acid 3k 1. -
Benzyl Chlorid Final
Survey of benzyl chloride (CAS no. 100-44-7) Part of the LOUS-review [Series Title and year] Consultation draft Title: Editing: Survey of benzyl chloride (CAS no. 100-44-7) Pia Brunn Poulsen, FORCE Technology Maria Strandesen, FORCE Technology Anders Schmidt, FORCE Technology Published by: Photography: The Danish Environmental Protection Agency [Name] Strandgade 29 1401 Copenhagen K Denmark Illustration: www.mst.dk/english [Name] Year: Map: [xxxx] [Name] ISBN no. [xxxxxx] Disclaimer: When the occasion arises, the Danish Environmental Protection Agency will publish reports and papers concerning research and development projects within the environmental sector, financed by study grants provided by the Danish Environmental Protection Agency. It should be noted that such publications do not necessarily reflect the position or opinion of the Danish Environmental Protection Agency. However, publication does indicate that, in the opinion of the Danish Environmental Protection Agency, the content represents an important contribution to the debate surrounding Danish environmental policy. While the information provided in this report is believed to be accurate, The Danish Environmental Protection Agency disclaims any responsibility for possible inaccuracies or omissions and consequences that may flow from them. Neither the Danish Environmental Protection Agency nor FORCE Technology or any individual involved in the preparation of this publication shall be liable for any injury, loss, damage or prejudice of any kind that may be caused by persons who have acted based on their understanding of the information contained in this publication. Sources must be acknowledged. 2 Survey of benzyl chloride (CAS no. 100-44-7) Contents Preface ...................................................................................................................... 6 Summary and conclusions ......................................................................................... 8 Sammenfatning og konklusion ............................................................................... -
A Systematic Review of Methamphetamine Precursor
REVIEW doi:10.1111/j.1360-0443.2011.03582.x A systematic review of methamphetamine precursor regulationsadd_3582 1..14 Rebecca McKetin1,2, Rachel Sutherland2, David A. Bright2 & Melissa M. Norberg2 Centre for Mental Health Research,The Australian National University, Canberra, Australia1 and National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia2 ABSTRACT Aims To assess the effectiveness of methamphetamine precursor regulations in reducing illicit methamphetamine supply and use. Methods A systematic review of 12 databases was used to identify studies that had evaluated the impact of methamphetamine precursor regulations on methamphetamine supply and/or use. The guidelines of the Effective Practice and Organization of Care Group (EPOC) of The Cochrane Collaboration were used to determine which study designs were included and assess their quality. Results Ten studies met the inclusion criteria. These studies evaluated 15 interventions (13 regulations and two related interdiction efforts), all of which were located in North America. Interventions had consistent impacts across various indicators of methamphetamine supply and use. Seven of the 15 interventions produced reductions in methamphetamine indicators (ranging from 12% to 77%). Two of the largest impacts were seen following interdiction efforts, involving the closure of rogue pharmaceutical companies. There was no evidence of a shift into other types of drug use, or injecting use, although the impact on the synthetic drug market was not examined. Null effects were related largely to the existence of alternative sources of precursor chemicals or the availability of imported methamphetamine. Conclusions Methamphetamine precursor regulations can reduce indicators of methamphetamine supply and use. Further research is needed to determine whether regu- lations can be effective outside North America, particularly in developing countries, and what impact they have on the broader synthetic drug market. -
Written Witness Statement for U.S. Sentencing Commission's Public
STATEMENT OF TERRENCE L. BOOS, PH.D. SECTION CHIEF DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION and CASSANDRA PRIOLEAU, PH.D. DRUG SCIENCE SPECIALIST DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION - - - BEFORE THE UNITED STATES SENTENCING COMMISSION - - - HEARING ON SENTENCING POLICY FOR SYNTHETIC DRUGS - - - OCTOBER 4, 2017 WASHINGTON, D.C. 1 Introduction New Psychoactive Substances (NPS) are substances trafficked as alternatives to well- studied controlled substances of abuse. NPS have demonstrated adverse health effects such as paranoia, psychosis, and seizures to name a few. Cathinones, cannabinoids, and fentanyl-related substances are the most common NPS drug classes encountered on the illicit drug market, all with negative consequences for the user to include serious injury and death. Our early experience saw substances being introduced from past research efforts in an attempt to evade controls. This has evolved to NPS manufacturers structurally altering substances at a rapid pace with unknown outcomes to targeting specific user populations. These substances represent an unprecedented level of diversity and consequences. Due to clandestine manufacture and unscrupulous trafficking, the user is at great risk. A misconception exists that these substances carry a lower risk of harm In reality, published reports from law enforcement, emergency room physicians and scientists, accompanied with autopsies from medical examiners, have clearly demonstrated the harmful and potentially deadly consequences of using synthetic cathinones. These substances are introduced in an attempt to circumvent drug controls and the recent flood of NPS remains a challenge for law enforcement and public health. The United Nations Office on Drugs and Crime reported over 700 NPS encountered.1 The manufacturers and traffickers make minor changes in the chemical structure of known substances of abuse and maintain the pharmacological effect. -
Safe Handling and Disposal of Chemicals Used in the Illicit Manufacture of Drugs
Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Safe handling and disposal of chemicals used in the illicit manufacture of drugs United Nations publication USD 26 Printed in Austria ISBN 978-92-1-148266-9 Sales No. E.11.XI.14 ST/NAR/36/Rev.1 V.11-83777—September*1183777* 2011—300 Guidelines for the Safe handling and disposal of chemicals used in the illlicit manufacture of drugs UNITED NATIONS New York, 2011 Symbols of United Nations documents are composed of letters combined with figures. Mention of such symbols indicates a reference to a United Nations document. ST/NAR/36/Rev.1 UNITED NATIONS PUBLICATION Sales No. E.11.XI.14 ISBN 978-92-1-148266-9 eISBN 978-92-1-055160-1 © United Nations, September 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Requests for permission to reproduce this work are welcomed and should be sent to the Secretary of the Publications Board, United Nations Headquarters, New York, N.Y. 10017, U.S.A. or also see the website of the Board: https://unp.un.org/Rights.aspx. Governments and their institutions may reproduce this work without prior authoriza- tion but are requested to mention the source and inform the United Nations of such reproduction. -
Precursor Chemicals Trends: U.S
Precursor Chemicals Trends: U.S. Perspectives Liqun L. Wong Unit Chief Drug & Chemical Evaluation Section Diversion Control Division United States Drug Enforcement Administration U.S. Drug Enforcement Administration 1 Opioid Health Crisis in U.S. Total Number of Overdose Deaths, 1999 ‐ 2018 120,000 100,000 Psychostimulants with abuse potential Benzodiazepines Methadone 12,801 80,000 Synthetic Opioids Natural and Semisynthetic Opioids 3,040 Cocaine 60,000 Heroin 31,473 40,000 Total Number of Deaths 12,588 20,000 14,762 15,073 0 ‐‐ ‐‐ ‐‐ 2018 Provisional data (12‐Month Period Ending on December 2018) No provisional data for benzodiazepine drug class U.S. Drug Enforcement Administration 2 Number of NPS Encounters in U.S. 140,000 Total Number of NPS Drug Reports by Drug Category and Year 96,212 87,094 120,000 Synthetic Cannabinoids 100,000 Synthetic Cathinones 45,882 80,000 Synthetic Opioids 17,968 865 5,769 60,000 1,298 14,998 14,527 15,715 40,000 16,215 Total Number of Drug Reports of Drug Total Number 744 9,461 10,938 7,209 11,535 43,197 20,000 39,812 35,980 34,628 29,526 678 23,699 26,350 20,233 636 743 29 3,291 0 23 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018* Source: National Forensic Laboratory Information System (NFLIS), DEA, Queried as of June 12, 2019. * NFLIS reporting still pending. U.S. Drug Enforcement Administration 3 Number of NPS in U.S. 250 Number of Drugs by Category 2009 ‐ 2018* 200 Synthetic Cannabinoids 29 45 Synthetic Cathinones 54 15 150 Synthetic Opioids 9 80 75 8 56 55 69 100 8 43 Number of NPS Drugs 39 5 50 23 86 93 94 88 81 4 62 67 2 12 44 19 0 2 6 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018* * NFLIS reporting still pending. -
Metabolic Engineering of Escherichia Coli to High Efficient Synthesis
Zhang et al. AMB Expr (2017) 7:105 DOI 10.1186/s13568-017-0407-0 ORIGINAL ARTICLE Open Access Metabolic engineering of Escherichia coli to high efcient synthesis phenylacetic acid from phenylalanine Lihua Zhang1,2, Qian Liu1,2, Hong Pan2*, Xun Li2 and Daoyi Guo1,2* Abstract Phenylacetic acid (PAA) is a fne chemical with a high industrial demand for its widespread uses. Whereas, microor- ganic synthesis of PAA is impeded by the formation of by-product phenethyl alcohol due to quick, endogenous, and superfuous conversion of aldehydes to their corresponding alcohols, which resulted in less conversation of PAA from aldehydes. In this study, an Escherichia coli K-12 MG1655 strain with reduced aromatic aldehyde reduction (RARE) that does duty for a platform for aromatic aldehyde biosynthesis was used to prompt more PAA biosynthesis. We establish a microbial biosynthetic pathway for PAA production from the simple substrate phenylalanine in E. coli with heterolo- gous coexpression of aminotransferase (ARO8), keto acid decarboxylase (KDC) and aldehyde dehydrogenase H (AldH) gene. It was found that PAA transformation yield was up to ~94% from phenylalanine in E. coli and there was no by-product phenethyl alcohol was detected. Our results reveal the high efciency of the RARE strain for production of PAA and indicate the potential industrial applicability of this microbial platform for PAA biosynthesis. Keywords: Metabolic engineering, Phenylacetic acid, Phenylalanine, Phenylacetaldehyde Introduction utilizing a nitrile hydratase and an amidase of Rhodococ- Phenylacetic acid (PAA) has received much attention on cus equi TG328 (Gilligan et al. 1993) or an arylacetoni- account of its extensive applications, which ofer the huge trilase from Pseudomonas fuorescens EBC191 (Sosedov demand.